High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression

Shen, Zhihua; Jiang, Xiaofan; Zeng, Chao; Zheng, Shaojiang; Luo, Botao; Zeng, Yimeng; Ding, Ran; Jiang, Huili; He, Qiyi; Guo, Junli; Jie, Wei

doi:10.1186/1471-2407-13-192

Cited by 51 publications

(57 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study revealed that UBE2C was expressed at low levels in non-cancerous and low-grade glioma tissues, whereas high-grade gliomas expressed UBE2C at increased levels. This result was consistent with previous studies, which have revealed the involvement of UBE2C in the malignant transformation of tissues and tumor progression (8,27,28). Okamoto et al (24) observed that the expression levels of UBE2C were extremely low in numerous normal tissues, but prominent in the majority of primary tumors and cancerous cell lines.…”

Section: Discussionsupporting

confidence: 82%

“…Ubiquitin-conjugating enzyme E2C (UBE2C) belongs to the E2 family, and is involved in mitotic cyclin destruction and cell cycle progression (8). UBE2C has been implicated in the carcinogenesis of certain tumors (9,10), and is overexpressed in various human cancers, including breast, esophageal, colon, lung, liver and ovarian cancers (11)(12)(13)(14)(15)(16).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

High expression of UBE2C is associated with the aggressive progression and poor outcome of malignant glioma

Kang

Zhang

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Ubiquitin-conjugating enzyme E2C (UBE2C) is a key regulator of cell cycle progression and is involved in the tumorigenesis of a variety of cancers. Previous studies have demonstrated that UBE2C is an important factor in the malignant progression of astrocytic tumors. However, the association between UBE2C expression and clinical prognosis of glioma patients has not been defined. In the present study, the expression of UBE2C in gliomas and non-cancerous brain tissues were detected by microarray and immunohistochemical analysis. The association between UBE2C expression and clinicopathological characteristics of the glioma patients was evaluated. The Kaplan-Meier method and multivariate Cox's proportional hazards model were used to analyze the survival time of the patients. The results demonstrated that the expression levels of UBE2C in anaplastic gliomas and glioblastoma (GBM) patients were significantly higher compared to low-grade gliomas, in microarray and immunohistochemistry analysis. A higher UBE2C expression was associated with a significantly decreased overall survival time in patients possessing anaplastic gliomas (P<0.01) and GBMs (P<0.05). Multivariate analysis of 80 GBM patients revealed that UBE2C expression was an independent prognostic factor. To the best of our knowledge, the present data suggest for the first time that UBE2C overexpression is strongly associated with an aggressive progression and poor outcome of malignant glioma. Therefore, UBE2C overexpression may be used as a predictor of poor prognosis in patients with malignant glioma.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Introductionmentioning

confidence: 99%

High expression of UBE2C is associated with the aggressive progression and poor outcome of malignant glioma

Kang

Zhang

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…UBE2C is required for the degradation of mitotic regulators in cooperation with anaphase-promoting complex/cyclosome (APC/ C) [20,21]. High expression of UBE2C is found in many human cancers of the brain, lung, cervix, colon, liver, thyroid, breast, and nasopharynx [22][23][24][25]. Depletion of UBE2C from cancer cells significantly reduced proliferation and induced cellular apoptosis.…”

Section: Introductionmentioning

confidence: 99%

UBE2S is associated with malignant characteristics of breast cancer cells

Ayesha¹,

Hyodo²,

Asano³

et al. 2015

Tumor Biol.

View full text Add to dashboard Cite

Ubiquitination is essential for various biological processes, such as signal transduction, intracellular trafficking, and protein degradation. Accumulating evidence has demonstrated that ubiquitination plays a crucial role in cancer development. In this report, we examine the expression and function of ubiquitin-conjugating enzyme E2S (UBE2S) in breast cancer. Immunohistochemical analysis revealed that UBE2S is highly expressed in breast cancer. The depletion of UBE2S by siRNA induced disruption of the actin cytoskeleton and focal adhesions. Interestingly, phosphorylation of FAK at Tyr397, which is important for the transduction of integrin-mediated signaling, was significantly reduced by UBE2S knockdown. We also show that UBE2S knockdown suppressed the malignant characteristics of breast cancer cells, such as migration, invasion, and anchorage-independent growth. Our results indicate that UBE2S could be a potential target for breast cancer treatment.

show abstract

“…Ubiquitination is a critical mechanism for selective protein degradation in eukaryotic cells, playing a pivotal role in protein homeostasis (1). Components of the ubiquitin-proteasome system (UPS) are under the control of three types of enzymes: Ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2) and ubiquitin-protein ligases (E3), which recognize and transfer ubiquitin, a 76-amino acids molecule, to the specific target proteins (1-3).…”

Section: Introductionmentioning

confidence: 99%

Induction of cell proliferation, clonogenicity and cell accumulation in S phase as a consequence of human UBE2Q1 overexpression

et al. 2016

View full text Add to dashboard Cite

Abstract.Ubiquitination is an important cellular mechanism with a pivotal role in the degradation of abnormal or short-lived proteins and the regulation of cell cycle and cell growth. The ubiquitin-proteasome pathway is altered in multiple types of human malignancies, including colorectal cancer (CRC). The alteration in the expression of the novel human gene ubiquitin-conjugating enzyme E2 Q1 (UBE2Q1), as a putative member of the E2 ubiquitin-conjugating enzyme family, has been reported in several malignancies, including carcinoma of the breast, hepatocellular and colorectal cancer, and pediatric acute lymphoblastic leukemia. In the present study, the effect of UBE2Q1 overexpression on cell growth, clonogenicity, motility and cell cycle was investigated in a CRC cell line. The UBE2Q1 gene was cloned in the pCMV6-AN-GFP expression vector. A series of stable transfectants of SW1116 cells overexpressing UBE2Q1 protein were established and confirmed by fluorescence microscopy and western blotting. Using these cells, MTT assay was performed to evaluate cell growth and proliferation, while crystal violet staining was used for clonogenicity assay. Cell cycle analysis was also performed to survey the ratio of cells accumulated in different phases of the cell cycle upon transfection. The motility of these cells was also studied using wound healing assay. UBE2Q1 transfectants exhibited a faster growth in cell culture, increased colony formation capacity and enhanced motility compared with control non-transfected cells and cells transfected with empty vector (mock-transfected cells). UBE2Q1 overexpression also resulted in a significant decrease in the number of cells accumulated in the G0/G1 phase of the cell cycle. The present findings suggest that UBE2Q1 may function as an oncogene that induces proliferation of cancer cells, and could be a novel diagnostic tool and a potential therapeutic target for CRC.

show abstract

High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression

Cited by 51 publications

References 39 publications

High expression of UBE2C is associated with the aggressive progression and poor outcome of malignant glioma

High expression of UBE2C is associated with the aggressive progression and poor outcome of malignant glioma

UBE2S is associated with malignant characteristics of breast cancer cells

Induction of cell proliferation, clonogenicity and cell accumulation in S phase as a consequence of human UBE2Q1 overexpression

Contact Info

Product

Resources

About